Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

The Quick Take
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to MarketWatch Top Stories.
Related
Markets
Midday Need to Know: Jobs data crush estimates, chip stocks rebound & more
Markets
Wisconsin reports measles-linked infant death as U.S. cases top 5,000
Markets
FREE Small Yankee Candle with Purchase Nov. 7-8th!
Mmmhhmm – this is a sweet deal! Stop by Yankee Candle on November 7th & 8th where you can grab a FREE small candle from the Merry & Bright Collection ($13…
Markets
